Wendell David Associates Inc. Has $46.82 Million Stock Position in Eli Lilly and Company $LLY

Wendell David Associates Inc. increased its stake in Eli Lilly and Company (NYSE:LLY) by 3.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,568 shares of the company’s stock after purchasing an additional 1,419 shares during the period. Eli Lilly and Company accounts for 4.8% of Wendell David Associates Inc.’s portfolio, making the stock its 5th largest holding. Wendell David Associates Inc.’s holdings in Eli Lilly and Company were worth $46,822,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently bought and sold shares of the stock. Brighton Jones LLC raised its position in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC raised its position in shares of Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares during the last quarter. Schnieders Capital Management LLC. raised its position in shares of Eli Lilly and Company by 16.7% during the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after acquiring an additional 1,141 shares during the last quarter. Flow Traders U.S. LLC bought a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at $356,000. Finally, Nebula Research & Development LLC bought a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at $749,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

LLY opened at $965.19 on Monday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The company has a fifty day simple moving average of $947.05 and a 200 day simple moving average of $987.36. The stock has a market cap of $911.93 billion, a P/E ratio of 34.29, a P/E/G ratio of 1.13 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same quarter in the prior year, the company earned $3.34 EPS. The firm’s quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts expect that Eli Lilly and Company will post 33.79 EPS for the current year.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q1 beat and raised outlook — Lilly reported revenue of $19.8B (+55.5% YoY) and non‑GAAP EPS of $8.55, topping estimates and lifting the company’s FY guidance, which supports stronger near‑term earnings growth. Results: Eli Lilly and Company Beat Earnings Expectations And Analysts Now Have New Forecasts
• Positive Sentiment: Blockbuster GLP‑1 sales and new oral pill expand market opportunity — multiple reports note Lilly’s metabolic/weight‑management drugs are delivering blockbuster revenue and that a new oral weight‑loss therapy broadens addressable market, underpinning upside potential. Eli Lilly Just Announced Fantastic News for Shareholders
• Positive Sentiment: Wall Street and media support — analysts (Truist, BofA) reaffirm buy/see upside after trial/data and earnings, and high‑profile coverage (e.g., Jim Cramer) is attracting fresh attention and flows into the name. Truist Reaffirms Buy on Eli Lilly (LLY) After Trial Success
• Neutral Sentiment: Sector‑level caution on GLP‑1 concentration — a Deloitte analysis flagged that GLP‑1s have shifted late‑stage pipeline value and could create a “bubble effect” in pharma, a macro/valuation risk to monitor even as Lilly benefits. ‘Bubble effect’: Weight loss drug fueled growth is putting the pharma sector at risk, report finds
• Neutral Sentiment: Supplemental investor materials — Lilly’s Q1 earnings presentation and analyst deep dives provide details on obesity‑franchise expansion and pipeline investment; useful for modeling but not immediate market movers. Eli Lilly and Company 2026 Q1 – Results – Earnings Call Presentation
• Neutral Sentiment: Unrelated biotech financing — a large offering by Cabaletta Bio is market news for biotech capital markets but does not directly affect Lilly’s fundamentals. Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
• Negative Sentiment: Price‑target trim by BofA — Bank of America lowered its LLY price target from $1,294 to $1,133 while keeping a Buy rating, a reminder some upside may already be priced in and that valuation sensitivity exists. BofA Securities cuts Eli Lilly price target to $1,133 from $1,294; maintains Buy rating

Wall Street Analyst Weigh In

Several brokerages have commented on LLY. Jefferies Financial Group set a $1,300.00 target price on shares of Eli Lilly and Company and gave the company a “buy” rating in a research report on Friday, March 13th. CICC Research upped their target price on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research report on Wednesday, February 11th. Zacks Research cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Berenberg Bank upped their price objective on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a research report on Thursday, February 19th. Finally, Leerink Partners lowered their price objective on shares of Eli Lilly and Company from $1,296.00 to $1,058.00 and set an “outperform” rating for the company in a research report on Monday, April 27th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,212.96.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.